Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
How can germline mutations distinguish risk for lethal and indolent prostate cancer?
Innovations in ovarian cancer treatment: PARP inhibitors
Where can PARP inhibitors be used
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer